1352485-19-8

Basic information

• Product Name: R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide
• Synonyms: R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide
• CAS NO: 1352485-19-8
• Molecular Weight: 520.622
• Mol File: 1352485-19-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide(1352485-19-8)
• EPA Substance Registry System: R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide(1352485-19-8)

Safety Data

• Hazardous Substances Data: 1352485-19-8(Hazardous Substances Data)

Upstream product

• 1380344-29-5 2-amino-2-(1-tert-butoxycarbonyl-piperidin-4-yl)-acetamide 
• 1380344-28-4 tert-butyl 4-(1-azido-2-methoxy-2-oxoethyl)piperidine-1-carboxylate 
• 881016-88-2 4-(bromo-methoxycarbonyl-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 84315-23-1 (trans)-3-(3,5-difluorophenyl)acrylic acid 
• 127561-33-5 4-(1H-indol-3-yl)-cyclohexanone 
• 127561-32-4 4-(1H-3-indolyl)cyclohexanone ethylene ketal 
• 143165-32-6 4-(1H-indol-3-yl)cyclohex-3-enone, ethylene ketal 
• 120-72-9 indole 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 175213-46-4 1-t-Butoxycarbonyl-4-(methoxycarbonylmethyl)piperidine 

Relevant articles and documents

4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).